S&P 500   4,587.93 (+0.80%)
DOW   35,684.45 (+0.55%)
QQQ   383.52 (+0.93%)
AAPL   152.83 (+2.67%)
MSFT   322.93 (-0.07%)
FB   313.39 (+0.37%)
GOOGL   2,912.20 (-0.42%)
TSLA   1,071.12 (+3.20%)
AMZN   3,442.78 (+1.48%)
NVDA   248.29 (+1.55%)
BABA   169.63 (+0.24%)
NIO   39.76 (+1.14%)
CGC   13.04 (+2.03%)
GE   104.12 (+0.26%)
AMD   122.49 (+0.17%)
MU   69.47 (+1.80%)
T   25.50 (+1.76%)
F   16.87 (+8.77%)
ACB   6.94 (+1.46%)
DIS   169.99 (+0.26%)
PFE   43.25 (+0.65%)
BA   206.40 (-0.10%)
AMC   35.42 (+1.90%)
S&P 500   4,587.93 (+0.80%)
DOW   35,684.45 (+0.55%)
QQQ   383.52 (+0.93%)
AAPL   152.83 (+2.67%)
MSFT   322.93 (-0.07%)
FB   313.39 (+0.37%)
GOOGL   2,912.20 (-0.42%)
TSLA   1,071.12 (+3.20%)
AMZN   3,442.78 (+1.48%)
NVDA   248.29 (+1.55%)
BABA   169.63 (+0.24%)
NIO   39.76 (+1.14%)
CGC   13.04 (+2.03%)
GE   104.12 (+0.26%)
AMD   122.49 (+0.17%)
MU   69.47 (+1.80%)
T   25.50 (+1.76%)
F   16.87 (+8.77%)
ACB   6.94 (+1.46%)
DIS   169.99 (+0.26%)
PFE   43.25 (+0.65%)
BA   206.40 (-0.10%)
AMC   35.42 (+1.90%)
S&P 500   4,587.93 (+0.80%)
DOW   35,684.45 (+0.55%)
QQQ   383.52 (+0.93%)
AAPL   152.83 (+2.67%)
MSFT   322.93 (-0.07%)
FB   313.39 (+0.37%)
GOOGL   2,912.20 (-0.42%)
TSLA   1,071.12 (+3.20%)
AMZN   3,442.78 (+1.48%)
NVDA   248.29 (+1.55%)
BABA   169.63 (+0.24%)
NIO   39.76 (+1.14%)
CGC   13.04 (+2.03%)
GE   104.12 (+0.26%)
AMD   122.49 (+0.17%)
MU   69.47 (+1.80%)
T   25.50 (+1.76%)
F   16.87 (+8.77%)
ACB   6.94 (+1.46%)
DIS   169.99 (+0.26%)
PFE   43.25 (+0.65%)
BA   206.40 (-0.10%)
AMC   35.42 (+1.90%)
S&P 500   4,587.93 (+0.80%)
DOW   35,684.45 (+0.55%)
QQQ   383.52 (+0.93%)
AAPL   152.83 (+2.67%)
MSFT   322.93 (-0.07%)
FB   313.39 (+0.37%)
GOOGL   2,912.20 (-0.42%)
TSLA   1,071.12 (+3.20%)
AMZN   3,442.78 (+1.48%)
NVDA   248.29 (+1.55%)
BABA   169.63 (+0.24%)
NIO   39.76 (+1.14%)
CGC   13.04 (+2.03%)
GE   104.12 (+0.26%)
AMD   122.49 (+0.17%)
MU   69.47 (+1.80%)
T   25.50 (+1.76%)
F   16.87 (+8.77%)
ACB   6.94 (+1.46%)
DIS   169.99 (+0.26%)
PFE   43.25 (+0.65%)
BA   206.40 (-0.10%)
AMC   35.42 (+1.90%)
NASDAQ:IPSC

Century Therapeutics Stock Forecast, Price & News

$21.50
+0.48 (+2.28 %)
(As of 10/28/2021 10:32 AM ET)
Add
Compare
Today's Range
$21.28
$21.50
50-Day Range
$16.36
$31.93
52-Week Range
$16.29
$32.90
Volume
294 shs
Average Volume
201,289 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive IPSC News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Century Therapeutics logo

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPSC
Employees
102
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.17 billion
Next Earnings Date
11/11/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.78 out of 5 stars

Medical Sector

802nd out of 1,372 stocks

Biological Products, Except Diagnostic Industry

122nd out of 197 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Century Therapeutics (NASDAQ:IPSC) Frequently Asked Questions

Is Century Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Century Therapeutics stock.
View analyst ratings for Century Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Century Therapeutics?

Wall Street analysts have given Century Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Century Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Century Therapeutics' next earnings date?

Century Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Century Therapeutics
.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.40) by $1.53.
View Century Therapeutics' earnings history
.

What price target have analysts set for IPSC?

4 brokerages have issued 1 year target prices for Century Therapeutics' stock. Their forecasts range from $33.00 to $40.00. On average, they anticipate Century Therapeutics' stock price to reach $36.25 in the next twelve months. This suggests a possible upside of 68.6% from the stock's current price.
View analysts' price targets for Century Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Century Therapeutics' key executives?

Century Therapeutics' management team includes the following people:
  • Dr. Osvaldo Flores, Pres, CEO & Director (Age 58, Pay $648.9k)
  • Dr. Michael C. Diem, Chief Bus. Officer (Age 50, Pay $298.54k)
  • Dr. Hyam I. Levitsky, Pres of R&D (Age 63, Pay $502.12k)
  • Mr. Douglas Carr CPA, VP of Fin. & Operations
  • Dr. Adrienne Farid Ph.D., Chief Operations Officer (Age 59)
  • Dr. Gregory Russotti Ph.D., Chief Technology Officer (Age 54)
  • Dr. Luis Borges, Chief Scientific Officer (Age 59)
  • Mr. Kenneth J. Dow J.D., VP of Law
  • Dr. Shane Williams Ph.D., Chief People Officer
  • Mr. Mark Wallet, Head of Immunology & VP

When did Century Therapeutics IPO?

(IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Century Therapeutics' stock symbol?

Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."

When does the company's lock-up period expire?

Century Therapeutics' lock-up period expires on Wednesday, December 15th. Century Therapeutics had issued 10,550,000 shares in its IPO on June 18th. The total size of the offering was $211,000,000 based on an initial share price of $20.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Strs Ohio (0.00%). Company insiders that own Century Therapeutics stock include Eli Casdin and Versant Venture Capital Vi, L.
View institutional ownership trends for Century Therapeutics
.

Which institutional investors are buying Century Therapeutics stock?

IPSC stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Century Therapeutics stock in the last two years include Eli Casdin, and Versant Venture Capital Vi, L.
View insider buying and selling activity for Century Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Century Therapeutics?

Shares of IPSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Century Therapeutics' stock price today?

One share of IPSC stock can currently be purchased for approximately $21.50.

How much money does Century Therapeutics make?

Century Therapeutics has a market capitalization of $1.17 billion.

How many employees does Century Therapeutics have?

Century Therapeutics employs 102 workers across the globe.

What is Century Therapeutics' official website?

The official website for Century Therapeutics is www.centurytx.com.

How can I contact Century Therapeutics?

The company can be reached via phone at 267-817-5790 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.